Erschienen in:
01.02.2018 | Review
Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials
verfasst von:
Shifu Hu, Qiong Yu, Yingying Wang, Mei Wang, Wei Xia, Changhong Zhu
Erschienen in:
Archives of Gynecology and Obstetrics
|
Ausgabe 5/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Polycystic ovary syndrome (PCOS) is a common endocrine disturbance affecting women in the reproductive age group. The present study aimed to compare the effects of letrozole (LE) and clomiphene citrate (CC) for ovulation induction in women with PCOS.
Methods
The PUBMED, Web of Science, and EMBASE databases were screened systematically for randomized controlled trials (RCTs) published from database inception to July 2017.
Results
Eleven RCTs involving 2255 patients were included, and data were independently extracted and analyzed using 95% risk ratios (RRs) and confidence intervals (CIs) based on a random- or fixed-effect model (as appropriate). Meta-analyses of nine RCTs comparing LE and CC ovulation induction, followed by timed intercourse, indicated that the former significantly increased the ovulation rate (RR = 1.18; 95% CI 1.03–1.36, P = 0.01), pregnancy rate (RR = 1.34; 95% CI 1.09–1.64, P = 0.006), and live birth rate (RR = 1.55; 95% CI 1.28–1.88, P < 0.00001). However, LE and CC did not differ significantly in terms of the multiple pregnancy and abortion rates. Furthermore, LE for ovulation induction significantly improved the pregnancy rate after IUI.
Conclusion
LE is superior to CC for ovulation induction in patients with PCOS.